gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 31 Jul 2015.

V-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog

erbB-2, HER2, c-erbB-2, HER-2/neu
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: HAD, CAN, EGFR, AGE, iMpact
Papers using erbB-2 antibodies
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium.
Supplier
Peterlongo Paolo, In PLoS ONE, 2010
... HER2 positivity was determined by IHC 3+ (HerceptTest, DAKO, Denmark) or fluorescence ...
Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray
Supplier
Lazutka Juozas et al., In Diagnostic Pathology, 2010
... Paraffin sections of the TMAs were cut for IHC (3 μm-thick) and HER2 FISH testing (4 μm-thick).IHC was performed on the TMA sections using Ultraview DAB detection kit on Ventana BenchMark XT staining system (Ventana Medical Systems, Tucson, Arizona, USA) [ ...
Genomic profiles specific to patient ethnicity in lung adenocarcinoma
Supplier
Lamy Pierre-Jean et al., In Breast Cancer Research : BCR, 2010
... Patients with primary HER-2-negative breast cancer were initially selected based on the level of HER-2 protein expression by IHC using the A485 monoclonal antibody (Dako A/S, Glostrup, Denmark) ...
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
Supplier
Shu Xiao Ou et al., In BMC Cancer, 2009
... The modified staining protocol for HER2/PR based on the DAKO EnVision™ G|2 Doublestain kit.
Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome
Supplier
Serrano María José et al., In Breast Cancer Research : BCR, 2009
... HER2 status was determined by IHC by using Herceptest (Dako) in all patients and ...
more suppliers
Papers on erbB-2
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.
New
Impact
Goldhirsch et al., Boston, United States. In J Clin Oncol, 27 Aug 2015
HER2-negative IDC and ILC were additionally classified as hormone receptor-positive with high (luminal B [LB] -like) or low (luminal A [LA] -like) proliferative activity by Ki-67 labeling index.
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.
New
Impact
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), In Lancet, 23 Aug 2015
RRs differed little by age, body-mass index, stage, grade, progesterone receptor status, or HER2 status.
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
New
Impact
Harris et al., Ann Arbor, United States. In J Clin Oncol, 20 Aug 2015
RESULTS: The literature search revealed 17 articles that met criteria for further review: 11 studies reporting discordances between primary tumors and metastases in expression of hormone receptors or human epidermal growth factor receptor 2 (HER2), one RCT that addressed the use of a biomarker to decide whether to change or continue a treatment regimen, and five prospective-retrospective studies that evaluated the clinical utility of biomarkers.
Targeted Therapy for Cancer in the Genomic Era.
New
Sledge et al., Stanford, United States. In Cancer J, 31 Jul 2015
The advent of cancer genomics has led to the development of many highly successful targeted therapies, primarily inhibitors of growth factor receptors and related kinases, including imatinib for chronic myeloid leukemia and trastuzumab for HER2-positive breast cancer.
Continued value of adjuvant anthracyclines as treatment for early breast cancer.
New
Impact
Di Leo et al., Prato, Italy. In Lancet Oncol, 31 Jul 2015
However, with the increasing use of other active drugs-mainly taxanes and trastuzumab in HER2-positive disease-coupled with concerns about anthracycline-associated toxic effects, there is debate about whether anthracyclines are still needed.
Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.
New
Impact
Gelber et al., Bethesda, United States. In J Clin Oncol, 22 Jul 2015
PURPOSE: We compared efficacy of trastuzumab versus no trastuzumab in patients with small (≤ 2 cm) human epidermal growth factor receptor 2 (HER2) -positive breast cancer treated in randomized trials.
Development of RNA aptamers as molecular probes for HER2(+) breast cancer study using cell-SELEX.
New
Abnous et al., Mashhad, Iran. In Iran J Basic Med Sci, 30 Jun 2015
Human epidermal growth factor receptor 2 (HER2) is specifically expressed on the surface of breast cancer cells.
Current approaches in treatment of triple-negative breast cancer.
Review
New
El-Hadaad et al., Al Manşūrah, Egypt. In Cancer Biol Med, 30 Jun 2015
TNBC is a term derived from tumors that are characterized by the absence of ER, PgR, and HER2.
Ductal Carcinoma In Situ of the Breast.
Review
New
Vaidya et al., Thāne, India. In Indian J Surg, Apr 2015
Adjuvant therapy includes antiestrogens like tamoxifen and human epidermal growth factor receptor 2 (HER2) suppression therapy.
Model-Based Design of a Decision Tree for Treating HER2+ Cancers Based on Genetic and Protein Biomarkers.
New
McDonagh et al., Cambridge, United States. In Cpt Pharmacometrics Syst Pharmacol, Mar 2015
Activating mutations in the PI3K and MAPK pathways (PIK3CA and KRAS), and expression of the HER3 ligand heregulin determined sensitivity to combinations of inhibitors against HER2 (lapatinib), HER3 (MM-111), AKT (MK-2206), and MEK (GSK-1120212; trametinib), in addition to the standard of care trastuzumab (Herceptin).
Thrombophilic polymorphisms are not associated with disease-free survival in breast cancer patients.
New
Karasoy et al., Ankara, Turkey. In Int J Clin Exp Med, Dec 2014
Data regarding patient's age, menopausal status, tumor size (T), lymph node status (N), cancer stage, tumor grade (G), estrogen and progesterone receptors, c-erbB2 expression, MTHFRC677T, FVL, and PTG20210A polymorphisms in DFS were examined by log-rank test and multivariate analyses.
Management of early breast cancer in older women: from screening to treatment.
Review
New
Errihani et al., Rabat, Morocco. In Breast Cancer (london), Dec 2014
We also discuss the indications of lymph node dissection, and we evaluate the benefit of adjuvant radiotherapy, chemotherapy, and the anti HER2 treatment for these women.
The Human Cathelicidin Antimicrobial Peptide LL-37 and Mimics are Potential Anticancer Drugs.
Review
New
Isogai et al., Sendai, Japan. In Front Oncol, Dec 2014
Indeed, previous studies have suggested that human LL-37 is involved in carcinogenesis via multiple reporters, such as FPR2 (FPRL1), epidermal growth factor receptor, and ERBb2, although LL-37 and its fragments and analogs also show anticancer effects in various cancer cell lines.
Targeting Insulin-Like Growth Factor Binding Protein-3 Signaling in Triple-Negative Breast Cancer.
Review
New
Martin et al., Sydney, Australia. In Biomed Res Int, Dec 2014
Because they lack estrogen and progesterone receptors and overexpression of HER2, TNBC are resistant to treatments that target these molecules, making the development of new therapies an important goal.
Interactions between αv-Integrin and HER2 and Their Role in the Invasive Phenotype of Breast Cancer Cells In Vitro and in Rat Brain.
New
Neuwelt et al., Portland, United States. In Plos One, Dec 2014
BACKGROUND: We tested the hypothesis that αv-integrin and the human epidermal growth factor receptor type 2 (HER2) interact with each other in brain trophic metastatic breast cancer cells and influence their invasive phenotype.
Quantitation of the effect of ErbB2 on epidermal growth factor receptor binding and dimerization.
GeneRIF
Pike et al., Saint Louis, United States. In J Biol Chem, 2012
a molecular explanation for the apparent preference of the EGF receptor for dimerizing with ErbB2 and suggest that the phosphorylation of ErbB2 occurs largely in the context of the EGFR/ErbB2 heterodimer
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.
GeneRIF
Müller et al., Hamburg, Germany. In Br J Cancer, 2012
Results show that elevated baseline sHER2 levels (>15 ng ml(1)) and a decrease of sHER2 levels (>20%) early after therapy initiation are both relevant criteria to predict response to lapatinib-based treatment.
HER2 status determination using RNA-ISH--a rapid and simple technique showing high correlation with FISH and IHC in 141 cases of breast cancer.
GeneRIF
García-Caballero et al., Santiago de Compostela, Spain. In Histol Histopathol, 2012
The probe developed for RNA-ISH represents a viable, effective possible alternative to FISH and IHC for analysing HER2 status in primary breast tumours.
[HER-2/neu-testing in breast cancer: is the immunocytochemistry competent?].
GeneRIF
Povilaĭtite et al., In Arkh Patol, 2012
Her-2/neu-testing in breast cancer: is the immunocytochemistry competent
[Different Her-2 status in infiltrative and intraductal components of the breast cancer].
GeneRIF
Petrov et al., In Arkh Patol, 2012
Different Her-2 status in infiltrative and intraductal components of the breast cancer
More papers using erbB-2 antibodies
Treatment of eccrine porocarcinoma with metastasis to the parotid gland using intensity-modulated radiation therapy: a case report
Supplier
Hoque Mohammad O., In PLoS ONE, 2009
... Tucson, AZ), PR (1E2, prediluted, Ventana Medical Systems), EGFR (3C6, prediluted, Ventana Medical Systems), and HER2 (4B5, prediluted, Ventana Medical Systems).
Novel design principles enable specific targeting of imaging and therapeutic agents to necrotic domains in breast tumors.
Supplier
Lebedeva Irina V., In PLoS ONE, 2009
... In these experiments, two different Affibody® molecules (Affibody, Stockholm, Sweden) were used: HER2-specific Affibody (His6-Z ...
p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC
Supplier
Vyzula Rostislav et al., In Diagnostic Pathology, 2009
... The expression of HER2 protein was determined by DAKO Herceptest (DAKO, Sweden) and ...
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer
Supplier
Chen Wei et al., In Breast Cancer Research : BCR, 2009
... Phospho-specific HER2 antibodies (Y877, Y1221/1222 and Y1248) were also purchased from Cell Signaling.
Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype.
Supplier
Falciani Francesco, In PLoS ONE, 2009
... Immunohistochemistry (IHC) status was available on most samples for ER (positivity cut-off: 10%), ERBB2 (0–3+ score, DAKO HercepTest, with >1+ defined ...
Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid
Supplier
Brünner Nils et al., In Histopathology, 2008
... The investigated antibodies are components of different IHC-based HER2 tests: PATHWAY® HER2 (clone 4B5; Ventana Medical Systems Inc., Tucson, AZ, USA), ...
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Supplier
Richardson Andrea L et al., In Breast Cancer Research : BCR, 2008
... (SP1 antibody, Neomarkers, Fremont, CA, USA), PR (PgR 636 antibody, Dako, Carpinteria, CA, USA) and HER2 (A085 antibody, Dako).
Pharmacokinetics and metabolism of the putative cancer chemopreventive agent cyanidin-3-glucoside in mice
Supplier
Luo Jia et al., In Molecular Cancer, 2008
... and ErbB2 (polyclonal) antibodies were purchased from Cell Signaling Technology Inc ...
The protein-tyrosine kinase Syk interacts with TRAF-interacting protein TRIP in breast epithelial cells
Supplier
Harrison D J et al., In British Journal of Cancer, 2008
... HER2 FISH PharmDx; Dako, Ely, Cambridge, UK) ...
Multiphoton time-domain fluorescence lifetime imaging microscopy: practical application to protein–protein interactions using global analysis
Supplier
Kong Anthony et al., In Oncotarget, 2008
... Anti-HER2 antibodies recognizing the intracellular residues were obtained from Cell Signaling Technology ...
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH
Supplier
Domagala Wenancjusz et al., In Virchows Archiv, 2008
... Expression of HER-2 and c-kit was tested using the HercepTest kit (Dako) and c-kit pharmDx kit ...
HER2 status and benefit from adjuvant trastuzumab in breast cancer
Supplier
Erşahin Çağatay et al., In Pathology Research International, 2007
... IHC analysis of ER, PR, and HER2 was performed on the Benchmark XT staining module (Ventana Medical Systems Inc, Tucson, AZ) ...
Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05) [abstract]
Supplier
De Laurentiis Michele et al., In Breast Cancer Research : BCR, 2007
... HER2 expression was assessed by immunohistochemistry with the polyclonal Dako test (Dako, Glostrup, Denmark) ...
The t10,c12 isomer of conjugated linoleic acid stimulates mammary tumorigenesis in transgenic mice over-expressing erbB2 in the mammary epithelium.
Supplier
Bauer Joseph Alan, In PLoS ONE, 2006
... Antibodies against HER2 were obtained from Abcam (Cambridge, MA) for Western ...
Standardization of HER2 testing: results of an international proficiency-testing ring study
Supplier
Kay Elaine et al., In Histopathology, 2006
... The cases supplied from Beaumont Hospital were assessed for HER-2 protein expression using Dako HercepTest® ( ...
A case of primary small cell carcinoma of the breast
Supplier
Bergkvist Leif et al., In Pathology Research International, 2006
... antibodies were used: estrogen receptor (Novocastra, clone 6F11, 1 : 100), progesterone receptor (Novocastra, clone 16, 1 : 100), c-erbB-2 oncoprotein (Dako, HER-2), mammoglobin (Dako, clone ...
Pterostilbene induces apoptosis and cell cycle arrest in human gastric carcinoma cells
Supplier
Chen Wei-Jen et al., In Evidence-based Complementary and Alternative Medicine : eCAM, 2006
... -actin, HER3 and HER2 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) ...
LIV-1 suppression inhibits HeLa cell invasion by targeting ERK1/2-Snail/Slug pathway
Supplier
Brandt B H et al., In British Journal of Cancer, 2006
... ductal invasive grade 2 and 3 breast cancer cases with very similar protein expression pattern (ER-positive, PR-positive, erbB2 0–2, Dako-Score/no-erbB2-amplification, EGFR-negative, p53 0–1, Ck ...
Prediction of breast tumor size by mammography and sonography--A breast screen experience
Supplier
Flynn Edward R et al., In Breast Cancer Research : BCR, 2006
... Anti-Her2 antibody was purchased from Bender MedSystems (now part of eBioscience, ...
Lowering of tumor interstitial fluid pressure reduces tumor cell proliferation in a xenograft tumor model.
Supplier
Najbauer Joseph, In PLoS ONE, 2005
... HER2- and Taq-specific Affibody Cloning, Overexpression, and Purification ...
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Supplier
Kiessling Rolf et al., In Journal of Translational Medicine, 2005
... Her2 status was routinely determined by immunohistochemistry using the antibodies CB11 (Ventana, and from 2007 Novocastra Leica, Wetzal, Germany), A485 (DAKO, ...
A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells
Supplier
Chernoff Jonathan et al., In Oncogene, 2005
... Monoclonal anti-ErbB2 was from Ventana Medical Systems, monoclonal anti-hemagglutinin (HA) (12CA5) ...
OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine
Supplier
Capala Jacek et al., In European Journal of Nuclear Medicine and Molecular Imaging, 2004
... HER2:342–Cys Affibody molecule was conjugated with ...
Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells
Supplier
Brodie A M H et al., In British Journal of Cancer, 2004
... The p-HER2 was purchased from Upstate (Temecula, CA, USA) and AR (SC-441) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) ...
Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation.
Supplier
Koch Karl-Wilhelm, In PLoS ONE, 2003
... Polyclonal rabbit anti phosphorylated ErbB1 (Tyr1068) and phosphorylated ErbB2 (Tyr1248) were purchased from Cell Signaling technology ...
Expression of luminal and basal cytokeratins in human breast carcinoma
Supplier
Pogoda Katarzyna et al., In Journal of Neuro-Oncology, 2003
... 6F11, Novocastra, dilution scale 1:100); against PR (Clone 16, Novocastra, dilution scale 1:200) and against HER2 (Polyclonal Hercep Test, DAKO).
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Supplier
Anderson Steven M et al., In Breast Cancer Research : BCR, 2003
... The MMTV-c-ErbB2 (line 202) transgenic mice [ ...
Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer
Supplier
Marcelo Aldaz C et al., In BMC Medical Genomics, 2003
... The data provided represent the statistical analysis of SAGE libraries from p53-Null, MMTV-erbB2 and C3(1)/SV40 transgenic mice mammary cancer models ...
The annexins
Supplier
Nenutil Rudolf et al., In Breast Cancer Research : BCR, 2003
... HER2/neu immunohistochemistryDako, polyclonal ...
Hsp90 (Heat Shock Protein 90) Inhibitor Occupancy Is a Direct Determinant of Client Protein Degradation and Tumor Growth Arrest in Vivo*
Supplier
Fritz Christian C. et al., In The Journal of Biological Chemistry, 2002
... Anti-Hsp90α antibody (clone 68) was from BD Biosciences; anti-Hsp90β antibody (clone H-114) and anti-HER2 (C-18) from Santa Cruz Biotechnology; and anti-EGFR, Akt (protein ...
Relationship between HER2 status and proliferation rate in breast cancer assessed by immunohistochemistry, fluorescence in situ hybridisation and standardised AgNOR analysis
Supplier
Ashankyty Ibraheem M. et al., In Pathology Research International, 2002
... hours in a humidity chamber using the following dilutions: p53 (clone DO-7, titer 1 : 50, Dako, Denmark), HER-2/neu (titer 1 : 50, Dako, Denmark), ER (clone 1D5, ...
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm
Supplier
Ghani Farooq et al., In Breast Cancer Research, 2002
... Patients eligible for participation were women with metastatic breast cancer who had HER2/neu overexpression as determined by immunohistochemistry (scores of 2+ or 3+ on the Dako Herceptest, Dako Corp, Carpinteria, ...
MHC class I negative phenotype of disseminated tumor cells in bone marrow is associated with poor survival in R0M0 breast cancer patients
Supplier
Kono K et al., In British Journal of Cancer, 2000
... Phycoerythrin (PE)-conjugated mouse anti-HER2/neu antibody (Becton Dickinson, Franklin Lakes, NJ, USA), ...
EGFR related peptides and their cognate receptors in breast cancer
Supplier
Thomas Shaji et al., In International Journal of Breast Cancer, 2000
... Immunohistochemistry for HER2-neu (Diagnostic biosystems HER2-neu, CD11 clone) ...
Untangling the ErbB signalling network
Supplier
Agus D B et al., In British Journal of Cancer, 2000
... Antibodies were purchased as follows: EGFR (#2232), HER2 (#2242), pEGFR (#2236), pHER2 (#2249) and pMAPK (#9101) from Cell Signaling Technology (Beverly, MA, USA), ...
Assessment of methods for tissue-based detection of the Her-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry
Supplier
Vijay Anand Reddy P. et al., In The Indian Journal of Medical Research, 1999
... immunostaining was performed using rabbit anti-human c-erbB-2 oncoprotein as primary antibody (Dako, Copenhagen, Denmark) at 1 : ...
A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data
Supplier
Bertucci François et al., In Breast Cancer Research : BCR, 1999
... The HER2 status was evaluated with the Dako scale (HercepTest kit scoring ...
Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression
Supplier
Eppenberger-Castori Serenella et al., In Breast Cancer Research, 1999
... EIA ErbB-2 positive samples correlate strongly with DAKO 3+ and with ErbB-2 ...
Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding.
Supplier
Lamartiniere Coral A. et al., In Environmental Health Perspectives, 1998
... A colony of mouse mammary tumor virus (MMTV)-erbB2/neu transgenic mice [FVB/N-TgN(MMTV-neu202Mul)] was established ...
c-Src is required for oxidative stress-mediated activation of big mitogen-activated protein kinase 1.
Supplier
Blagosklonny Mikhail V., In PLoS ONE, 1996
... HER2 was analyzed using the Dako Herceptest kit (DakoCytomation, Carpinteria, ...
Mechanisms of cellular penetration and nuclear localization of an anti-double strand DNA autoantibody
Supplier
Kim Yong-Sung et al., In Nucleic Acids Research, 1995
... and Her218 was placed between the ATG start codon and EGFP coding sequence in the pEGFP-N1 plasmid (Clontech), resulting in pG ...
Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up
Supplier
Meneses-Garcia A. et al., In ISRN Oncology, 1991
... Immunohistochemical staining for the HER2 protein was performed using the DAKO HercepTest immunocyto-chemical assay (DAKO, ...
Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression
Supplier
Hamad Mohammad Al et al., In Breast Cancer Research, 1989
... primary antibodies against ER and PR (Biogenex, San Ramon, Ca, USA) was 1:130, and for Her-2/neu (Dako, Carpintera, Ca, USA) 1:50 ...
Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness
Supplier
Blankenstein Thomas et al., In The Journal of Experimental Medicine, 1989
... Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune ...
Integration and generalization of Kappa for multiple raters
Supplier
Kreipe H. H. et al., In Virchows Archiv, 1979
... IHC immunostaining was conducted using HercepTest™ (Dako Denmark A/S, Glostrup, Denmark) and/or the PATHWAY® HER2/neu (4B5) antibody (Ventana Medical Systems SA, Illkirch, France) ...
share on facebooktweetadd +1mail to friends